OA11379A - Combination of an aldose reductase inhibitor and aglycogen phosphrylase inhibitor. - Google Patents

Combination of an aldose reductase inhibitor and aglycogen phosphrylase inhibitor. Download PDF

Info

Publication number
OA11379A
OA11379A OA1200000137A OA1200000137A OA11379A OA 11379 A OA11379 A OA 11379A OA 1200000137 A OA1200000137 A OA 1200000137A OA 1200000137 A OA1200000137 A OA 1200000137A OA 11379 A OA11379 A OA 11379A
Authority
OA
OAPI
Prior art keywords
amide
chloro
indole
hydroxy
oxo
Prior art date
Application number
OA1200000137A
Other languages
English (en)
Inventor
Dennis Jay Hoover
Bernard Hulin
Banavara Lakshman Mylari
Judith Lee Treadway
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA11379A publication Critical patent/OA11379A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Noise Elimination (AREA)
  • Superheterodyne Receivers (AREA)
OA1200000137A 1997-11-21 2000-05-12 Combination of an aldose reductase inhibitor and aglycogen phosphrylase inhibitor. OA11379A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6636597P 1997-11-21 1997-11-21

Publications (1)

Publication Number Publication Date
OA11379A true OA11379A (en) 2004-01-28

Family

ID=22069038

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000137A OA11379A (en) 1997-11-21 2000-05-12 Combination of an aldose reductase inhibitor and aglycogen phosphrylase inhibitor.

Country Status (38)

Country Link
EP (1) EP1032424B9 (no)
JP (1) JP2002504478A (no)
KR (2) KR20010032304A (no)
CN (1) CN1279617A (no)
AP (1) AP911A (no)
AR (1) AR016423A1 (no)
AT (1) ATE205403T1 (no)
AU (1) AU733304B2 (no)
BG (1) BG104435A (no)
BR (1) BR9814698A (no)
CA (1) CA2310069A1 (no)
DE (1) DE69801680T2 (no)
DK (1) DK1032424T3 (no)
DZ (1) DZ2656A1 (no)
EA (1) EA002365B1 (no)
ES (1) ES2161548T3 (no)
GR (1) GR3037071T3 (no)
GT (1) GT199800166A (no)
HR (1) HRP20000327A2 (no)
HU (1) HUP0100272A3 (no)
ID (1) ID24524A (no)
IL (1) IL135713A0 (no)
IS (1) IS5453A (no)
MA (1) MA26568A1 (no)
NO (1) NO20002164L (no)
OA (1) OA11379A (no)
PA (1) PA8462301A1 (no)
PE (1) PE135399A1 (no)
PL (1) PL340643A1 (no)
PT (1) PT1032424E (no)
SK (1) SK7222000A3 (no)
TN (1) TNSN98211A1 (no)
TR (1) TR200001451T2 (no)
UA (1) UA57811C2 (no)
UY (1) UY25258A1 (no)
WO (1) WO1999026659A1 (no)
YU (1) YU30700A (no)
ZA (1) ZA9810636B (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1150674A1 (en) * 1999-02-12 2001-11-07 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
ATE385421T1 (de) 2000-01-21 2008-02-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002098429A1 (en) * 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7674913B2 (en) 2003-11-12 2010-03-09 Phenomix Corporation Heterocyclic boronic acid compounds
WO2006017292A1 (en) 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CN102908350B (zh) 2005-09-14 2014-07-23 武田药品工业株式会社 用于治疗糖尿病的二肽基肽酶抑制剂
US8318941B2 (en) 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8546394B2 (en) 2007-04-17 2013-10-01 Bristol-Myers Squibb Company Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
PE20090213A1 (es) 2007-05-04 2009-02-28 Bristol Myers Squibb Co Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos
PE20090222A1 (es) 2007-05-04 2009-03-27 Bristol Myers Squibb Co Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
US8003796B2 (en) 2007-07-17 2011-08-23 Bristol-Myers Squibb Company Pyridone GPR119 G protein-coupled receptor agonists
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
PT2531501E (pt) 2010-02-03 2014-02-17 Takeda Pharmaceutical Inibidores da cinase de regulação do sinal de apoptose 1
SG184168A1 (en) 2010-04-08 2012-10-30 Bristol Myers Squibb Co Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
ES2559209T3 (es) 2010-04-14 2016-02-11 Bristol-Myers Squibb Company Nuevos activadores de la glucocinasa y métodos de uso de los mismos
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
CN102971311B (zh) 2010-05-06 2015-07-08 百时美施贵宝公司 作为gpr119调节剂的二环杂芳基化合物
EP3042654A1 (en) 2011-01-20 2016-07-13 Bionevia Pharmaceuticals Inc. Modified release compositions of epalrestat or a derivative thereof and methods for using the same
US9174965B2 (en) 2012-05-16 2015-11-03 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
US9580422B2 (en) 2013-10-22 2017-02-28 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
MA45714A (fr) 2016-07-22 2019-05-29 Bristol Myers Squibb Co Activateurs de glucokinase et leurs procédés d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4825448A (en) * 1986-08-07 1989-04-25 International Mobile Machines Corporation Subscriber unit for wireless digital telephone system
DE3889326D1 (de) * 1988-05-27 1994-06-01 Itt Ind Gmbh Deutsche Korrekturschaltung für ein digitales Quadratur-Signalpaar.
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
JP3314938B2 (ja) * 1995-06-06 2002-08-19 ファイザー・インコーポレーテッド グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体
MX9709874A (es) * 1995-06-06 1998-03-31 Pfizer N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.

Also Published As

Publication number Publication date
IS5453A (is) 2000-04-14
AR016423A1 (es) 2001-07-04
CN1279617A (zh) 2001-01-10
AU733304B2 (en) 2001-05-10
TR200001451T2 (tr) 2002-06-21
UA57811C2 (uk) 2003-07-15
MA26568A1 (fr) 2004-12-20
EP1032424A1 (en) 2000-09-06
DE69801680D1 (de) 2001-10-18
PA8462301A1 (es) 2000-05-24
DZ2656A1 (fr) 2003-03-22
PT1032424E (pt) 2001-12-28
ES2161548T3 (es) 2001-12-01
ATE205403T1 (de) 2001-09-15
TNSN98211A1 (fr) 2005-03-15
PL340643A1 (en) 2001-02-12
HUP0100272A2 (hu) 2001-06-28
ZA9810636B (en) 2000-05-22
EA002365B1 (ru) 2002-04-25
KR20010032304A (ko) 2001-04-16
YU30700A (sh) 2002-12-10
CA2310069A1 (en) 1999-06-03
DK1032424T3 (da) 2001-11-19
KR100661214B1 (ko) 2006-12-26
AP911A (en) 2000-12-07
BR9814698A (pt) 2000-10-03
GR3037071T3 (en) 2002-01-31
EP1032424B1 (en) 2001-09-12
WO1999026659A1 (en) 1999-06-03
PE135399A1 (es) 2000-01-15
HRP20000327A2 (en) 2001-02-28
EA200000433A1 (ru) 2000-12-25
DE69801680T2 (de) 2002-02-07
IL135713A0 (en) 2001-05-20
GT199800166A (es) 2000-04-19
JP2002504478A (ja) 2002-02-12
NO20002164D0 (no) 2000-04-27
NO20002164L (no) 2000-07-19
HUP0100272A3 (en) 2002-11-28
ID24524A (id) 2000-07-20
SK7222000A3 (en) 2001-09-11
KR20010032300A (ko) 2001-04-16
EP1032424B9 (en) 2004-10-06
UY25258A1 (es) 2000-12-29
AU9555898A (en) 1999-06-15
AP9801401A0 (en) 1998-12-31
BG104435A (bg) 2001-01-31

Similar Documents

Publication Publication Date Title
AU733304B2 (en) Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor
AU717547B2 (en) Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
AP624A (en) Substituted n-(indole-2-carbonyl)-b- alanimamides and derivatives as antidiabetic agents.
US5998463A (en) Glycogen phosphorylase inhibitors
CA2279732A1 (en) Method of inhibition of human glycogen phosphorylase
NZ286460A (en) N-(indole-2-carbonyl)aminoacid derivatives, n-(2-aminoacyl)azacyclic intermediates and pharmaceutical compositions
US6277877B1 (en) Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors
US6846820B2 (en) Substituted N-(indole-2-carbonyl) -amides and derivatives as glycogen phosphorylase inhibitors
EP1134213A2 (en) Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides
JP2000500490A (ja) 糖尿病治療用の４−ヒドロキシクマリン−３−カルボキシアミド
MXPA00005025A (en) Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor
CZ20001837A3 (cs) Kombinace inhibitoru aldosa reduktasy a inhibitoru glykogen fosforylasy